Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLO1 | Q04760 | 3/20 | 0.51 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 5/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045097 | 0.85 | SLC40A1 (0.49) | GLO1PRKD1HTR2AHTR2CSLC6A4 | |
| SCHEMBL3619544 | 0.84 | PRKD1 (0.44) | GLO1PRKD1KDM4EALDH1A1HPGD | |
| SCHEMBL7045566 | 0.84 | PRKD1 (0.49) | GLO1PRKD1HTR2AHTR2CSLC6A4 | |
| SCHEMBL3616367 | 0.80 | HTR6 (0.51) | PRKD1HTR2AHTR2CSLC6A4HTR6 | |
| Trifluoroacetic Acid SCHEMBL1380171 | 0.79 | L3MBTL1 (0.43) | PRKD1HTR2AHTR2CSLC6A4HTR6 | |
| SCHEMBL1379328 | 0.78 | TDP1 (0.50) | PRKD1KDM4EALDH1A1HPGDHTR6 | |
| SCHEMBL3616470 | 0.78 | MEN1 (0.50) | PRKD1ALDH1A1HTR2AHTR2CSLC6A4 | |
| SCHEMBL1380555 | 0.78 | NFKBIA (0.51) | GLO1PRKD1KDM4EALDH1A1HPGD | |
| SCHEMBL1377405 | 0.76 | SLC40A1 (0.54) | PRKD1HTR6HTR1ADRD2HTR7 | |
| SCHEMBL3623702 | 0.75 | SLC40A1 (0.58) | PRKD1ALDH1A1HTR2CHTR6HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4731114-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | claimed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | claimed |
| EP-1412325-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2004-04-28 | — | — | EP | claimed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | claimed |
| WO-2002100822-A1 | SUBSTITUTED SULFONAMIDE COMPOUNDS, PROCESS FOR THEIR USE AS MEDICAMENT FOR THE TREATMENT OF CNS DISORDERS, OBESITY AND TYPE II DIABETES | BIOVITRUM AB (SE) | 2002-12-19 | — | — | WO | claimed |
| US-20100222330-A1 | New Compounds | BIOVITRUM AB (SE) | 2010-09-02 | — | — | US | disclosed |
| US-7572787-B2 | Substituted naphthalene sulfonamides | BIOVITRUM AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20070066598-A1 | Compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066599-A1 | New compounds | BIOVITRUM AB, A SWEDEN CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066600-A1 | Compounds | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2007-03-22 | — | — | US | disclosed |
| US-7144883-B2 | Bicyclic sulfonamide compounds | BIOVITRUM AB (SE) | 2006-12-05 | — | — | US | disclosed |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | PROXIMAGEN NEUROSCIENCE PLC (GB) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066599-A1 | New compounds | SULT2A1, GPR119, STS | GLO1 639/4885PRKD1 4439/4885KDM4E 3591/4885 |
| US-20070066598-A1 | Compounds | SULT2A1, STS, SLC5A2 | GLO1 752/4885PRKD1 4705/4885KDM4E 3286/4885 |
| US-20030158202-A1 | Substituted fused ring sulfonamides containing, e.g., naphthalene, isoquinoline, quinoline, benzofuran or benzothiophene rings; treatment of conditions relating to obesity, type II diabetes and CNS disorders | SULT2A1, SULT1A1, SULT1E1 | GLO1 1409/4885PRKD1 4604/4885KDM4E 3527/4885 |
| US-20070066600-A1 | Compounds | SULT2A1, STS, SLC5A2 | GLO1 752/4885PRKD1 4705/4885KDM4E 3286/4885 |
| US-20100222330-A1 | New Compounds | SULT2A1, GPR119, STS | GLO1 639/4885PRKD1 4439/4885KDM4E 3591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.